Dr Jian Li recently published a paper in Clin Lympohma Myeloma Leuk. titled "New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts – A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR)"
Dr Adam Irving published a manuscript titled "A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data" in Pharmacoeconomics.
Rounding out the three publications, Dr Sueh-Li Lim published her paper in Br J Haematol titled "No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry"
Congratulations to all three of our first authors, and thank you to all the patients, MRDR site staff and investigators for your contributions to such important research.